0.55
—
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Goldenwell Biotech
From its filings with the US Securities and Exchange Commission
Goldenwell Biotech is based in Solon, Ohio and is incorporated in Nevada. Its shares trade on OTC under the ticker GWLL. The SEC classifies its business as food and kindred products. In the fiscal year to 31 December 2025, it reported revenue of $55 and a net loss of $296,471. At that date it held total assets of $36,120 and shareholders' equity of −$343,713.
Goldenwell Biotech, Inc. was incorporated on August 20, 2019. Our fiscal year end is December 31, and we have no subsidiaries. Our business offices are currently located at 7316 Capilano Dr., Solon, Ohio 44139. We do not conduction operations and only receive mail at such location.
The tables and information below are derived from our audited financial statements as of December 31, 2025.
Effective July 20, 2020, the Company entered into an Exclusive License Agreement with Australian Trefoil Health Technologies Pty Ltd (the “Australian Trefoil License Agreement”), pursuant to which the Company has licensed from Australian Trefoil the technology and packaging designs underlying the Sugar Master and DNA Repair products, and other products of the Company. The term of the Australian Trefoil License Agreement is for the term of the underlying patent and covers all territories in the world, except China, and the term expires on November 15, 2025. The Company paid consideration of $10.00 for entering into the Australian Trefoil License Agreement. Australian Trefoil Health Technologies Pty Ltd is controlled by Li Yang, a director of the Company.
Quoted from its 10-K, filed 1 Jul 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- N/A
- Industry
- N/A
- Listed since
- 7 Dec 2021
- Website
- goldenwellbiotech.com ↗
- Head office
- 7316 CAPILANO DR., SOLON, OH, 44139
- Incorporated in
- NV
- Classification
- Food and Kindred Products
- Filer status
- <br>Emerging growth company
Leadership
Pay as last reported
- Mr. Shuang LiuPresident, Chief Executive Officer, Director, since 2019
- Mr. Li YangTreasurer, Director, since 2019
- Ms. Xie HuaSecretary, Director, since 2019$44,174
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Headquartered in Twinsburg, Ohio with an IPO in 2021-12-07
- Offers products under two categories: Polypeptide Freeze-dried Powder and Solid Tablets
- Products include JI MAI-Bovine Cardiac Vascular Active Peptide and Double Proline AG
Weaknesses
- Company is a development stage company with no specified industry or sector
- Products are categorized under health care and supplement without detailed market data
- No information provided on financial performance or market share
Opportunities
- Potential growth in health care and supplement product markets
- Expansion of product lines such as Cartilage Peptide-Type II collagen peptide
- Increasing demand for natural herbal polypeptides and collagen products
Threats
- Untrusted source description may lead to inaccurate information
- Development stage company faces high risk in R&D and market entry
- Lack of industry and sector classification may hinder market positioning
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.